1. Home
  2. HEPA vs PTIX Comparison

HEPA vs PTIX Comparison

Compare HEPA & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HEPA
  • PTIX
  • Stock Information
  • Founded
  • HEPA 2013
  • PTIX 1994
  • Country
  • HEPA United States
  • PTIX United States
  • Employees
  • HEPA N/A
  • PTIX N/A
  • Industry
  • HEPA Biotechnology: Pharmaceutical Preparations
  • PTIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • HEPA Health Care
  • PTIX Health Care
  • Exchange
  • HEPA Nasdaq
  • PTIX Nasdaq
  • Market Cap
  • HEPA 4.7M
  • PTIX 3.9M
  • IPO Year
  • HEPA N/A
  • PTIX 2016
  • Fundamental
  • Price
  • HEPA $0.68
  • PTIX $0.64
  • Analyst Decision
  • HEPA Hold
  • PTIX
  • Analyst Count
  • HEPA 1
  • PTIX 0
  • Target Price
  • HEPA N/A
  • PTIX N/A
  • AVG Volume (30 Days)
  • HEPA 39.0K
  • PTIX 247.6K
  • Earning Date
  • HEPA 11-26-2024
  • PTIX 11-29-2024
  • Dividend Yield
  • HEPA N/A
  • PTIX N/A
  • EPS Growth
  • HEPA N/A
  • PTIX N/A
  • EPS
  • HEPA N/A
  • PTIX N/A
  • Revenue
  • HEPA N/A
  • PTIX N/A
  • Revenue This Year
  • HEPA N/A
  • PTIX N/A
  • Revenue Next Year
  • HEPA N/A
  • PTIX N/A
  • P/E Ratio
  • HEPA N/A
  • PTIX N/A
  • Revenue Growth
  • HEPA N/A
  • PTIX N/A
  • 52 Week Low
  • HEPA $0.55
  • PTIX $0.49
  • 52 Week High
  • HEPA $4.47
  • PTIX $1.87
  • Technical
  • Relative Strength Index (RSI)
  • HEPA 52.88
  • PTIX 49.61
  • Support Level
  • HEPA $0.60
  • PTIX $0.52
  • Resistance Level
  • HEPA $0.68
  • PTIX $1.09
  • Average True Range (ATR)
  • HEPA 0.05
  • PTIX 0.15
  • MACD
  • HEPA 0.00
  • PTIX 0.01
  • Stochastic Oscillator
  • HEPA 87.80
  • PTIX 20.91

About HEPA Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

About PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Share on Social Networks: